NO20073414L - Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4) - Google Patents

Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)

Info

Publication number
NO20073414L
NO20073414L NO20073414A NO20073414A NO20073414L NO 20073414 L NO20073414 L NO 20073414L NO 20073414 A NO20073414 A NO 20073414A NO 20073414 A NO20073414 A NO 20073414A NO 20073414 L NO20073414 L NO 20073414L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
angptl4
angiopotetin
protein
neutralizing
Prior art date
Application number
NO20073414A
Other languages
English (en)
Norwegian (no)
Inventor
E-Chiang Lee
Gregory M Landes
Kuy Chung
Ling Chen
Urvi Desai
David Reed Powell
Seokjoo Hong
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NO20073414L publication Critical patent/NO20073414L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20073414A 2005-01-07 2007-07-03 Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4) NO20073414L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64202205P 2005-01-07 2005-01-07
PCT/US2006/000184 WO2006074228A1 (en) 2005-01-07 2006-01-06 Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )

Publications (1)

Publication Number Publication Date
NO20073414L true NO20073414L (no) 2007-10-02

Family

ID=36177590

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073414A NO20073414L (no) 2005-01-07 2007-07-03 Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)

Country Status (14)

Country Link
US (3) US7655762B2 (ko)
EP (1) EP1846452B1 (ko)
JP (1) JP5366406B2 (ko)
KR (1) KR101387781B1 (ko)
CN (1) CN101128485B (ko)
AU (1) AU2006204001B2 (ko)
BR (1) BRPI0606432A2 (ko)
CA (1) CA2594233C (ko)
EA (1) EA016185B1 (ko)
IL (1) IL184235A (ko)
MX (1) MX2007008256A (ko)
NO (1) NO20073414L (ko)
WO (1) WO2006074228A1 (ko)
ZA (1) ZA200705980B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7740846B2 (en) * 2004-07-20 2010-06-22 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1781698B1 (en) 2004-07-20 2016-07-06 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
WO2011046515A1 (en) 2009-10-14 2011-04-21 Nanyang Technological University Antiproliferative agent
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
CA2831958A1 (en) * 2011-04-08 2012-10-11 Access Business Group International Llc Counter wound inductive power supply
CN102242198A (zh) * 2011-05-25 2011-11-16 信阳师范学院 通过angptl4基因多态性进行牛育种方法
CN103782177B (zh) * 2011-08-08 2017-10-03 南洋理工大学 血管生成素样4及其在调节细胞渗漏中的用途
EP2833892A4 (en) * 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CN104244978A (zh) * 2012-04-16 2014-12-24 瑞泽恩制药公司 通过施用丝氨酸蛋白酶抑制剂治疗或预防流感病毒感染的方法
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
MA43186B1 (fr) * 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
CN113015803A (zh) * 2018-11-13 2021-06-22 利皮药业有限公司 影响脂肪酸代谢调控的angptl4寡核苷酸
US20220389088A1 (en) * 2019-10-29 2022-12-08 University Of Florida Research Foundation, Incorporated Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use
CN115708872A (zh) * 2022-11-03 2023-02-24 中国科学院深圳先进技术研究院 抗血管生成素样蛋白4抗体在制备抑制炎症因子表达的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2001077151A2 (en) 2000-04-07 2001-10-18 Millennium Pharmaceuticals, Inc. Fdrg proteins and nucleic acid molecules and uses therefor
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
CN1141318C (zh) * 2001-02-28 2004-03-10 中国医学科学院血液学研究所 人促血液血管细胞生成素及其制造方法
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
US7740846B2 (en) * 2004-07-20 2010-06-22 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1781698B1 (en) * 2004-07-20 2016-07-06 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein

Also Published As

Publication number Publication date
BRPI0606432A2 (pt) 2009-06-30
EP1846452B1 (en) 2014-08-06
IL184235A (en) 2012-10-31
AU2006204001A1 (en) 2006-07-13
EP1846452A1 (en) 2007-10-24
CN101128485B (zh) 2012-09-26
EA200701452A1 (ru) 2008-02-28
US20110008359A1 (en) 2011-01-13
US8092796B2 (en) 2012-01-10
JP2008526857A (ja) 2008-07-24
WO2006074228A1 (en) 2006-07-13
US20120171217A1 (en) 2012-07-05
US8591891B2 (en) 2013-11-26
EA016185B1 (ru) 2012-03-30
ZA200705980B (en) 2009-01-28
CA2594233C (en) 2015-02-24
KR20070107696A (ko) 2007-11-07
JP5366406B2 (ja) 2013-12-11
MX2007008256A (es) 2007-12-06
CN101128485A (zh) 2008-02-20
AU2006204001B2 (en) 2011-06-16
US7655762B2 (en) 2010-02-02
US20060222645A1 (en) 2006-10-05
KR101387781B1 (ko) 2014-04-21
IL184235A0 (en) 2007-10-31
CA2594233A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
NO20073414L (no) Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)
NO20092215L (no) Monoklonale antistoffer mot ANGPTL3
NO2017032I1 (no) bezlotoksumab
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
PH12015501848A1 (en) Binding agents
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
MY174493A (en) Binding agents
AR083747A1 (es) Anticuerpos anti-il-23
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
CR9471A (es) Anticuerpos de p-caderina
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2009008916A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
DK1861711T3 (da) Anvendelse af MGC4504
CR20140081A (es) Agentes de fijación

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application